Posted by Michael Wonder on 11 Feb 2023
Health Canada approves Adtralza (tralokinumab) for the treatment of adolescents aged 12 to 17 with moderate to severe atopic dermatitis
8 February 2023 - Adtralza is the first treatment for adolescents with moderate to severe atopic dermatitis specifically targeting the interleukin-13 cytokine, one of the drivers of atopic dermatitis signs and symptoms.
LEO Pharma today announced the Health Canada approval of Adtralza (tralokinumab) for adolescent patients aged 12 to 17 with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
